Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.34 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.34 |
| ▸ | IGFBP3 | P17936 | 2/20 | 0.34 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.34 |
| ▸ | IGFBP5 | P24593 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6080353 | 0.84 | NQO2 (0.41) | GPR35KDM4EMAPT | |
| SCHEMBL6592548 | 0.80 | IGFBP3 (0.40) | IGFBP3GPR35IGFBP5KDM4EMAPT | |
| SCHEMBL6079960 | 0.80 | GPR35 (0.38) | IGFBP3GPR35IGFBP5KDM4EMAPT | |
| Hydrochloric Acid SCHEMBL6079789 | 0.79 | IGFBP3 (0.40) | IGFBP3GPR35IGFBP5KDM4EMAPT | |
| SCHEMBL6591416 | 0.79 | VCAM1 (0.43) | IGFBP3MAPTKMT2A | |
| SCHEMBL6591421 | 0.79 | VCAM1 (0.43) | IGFBP3MAPTKMT2A | |
| SCHEMBL6080671 | 0.78 | GPR35 (0.43) | IGFBP3GPR35IGFBP5KDM4EMAPT | |
| SCHEMBL6598349 | 0.78 | GPR35 (0.39) | IGFBP3GPR35IGFBP5KDM4EMAPT | |
| SCHEMBL6080512 | 0.78 | GPR35 (0.43) | IGFBP3GPR35IGFBP5KDM4EMAPT | |
| SCHEMBL6591404 | 0.75 | GPR35 (0.35) | XDHGPR35KDM4EMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
| EP-1451159-A1 | COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF | NEURO3D (FR) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003010146-A1 | COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF | NEURO3D (FR) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | XDH 128/4885SLC22A12 2041/4885IGFBP3 4812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.